WO2025136346 - INDAZOLE CONTAINING COMPOUNDS AND METHODS OF USE
National phase entry is expected:
Publication Number
WO/2025/136346
Publication Date
26.06.2025
International Application No.
PCT/US2023/074842
International Filing Date
19.12.2023
Title **
[English]
INDAZOLE CONTAINING COMPOUNDS AND METHODS OF USE
[French]
COMPOSÉS CONTENANT DE L'INDAZOLE ET PROCÉDÉS D'UTILISATION
Applicants **
AMGEN INC.
Inventors
PETTUS, Liping
SMALIGO, Andrew
LI, Xiaofen
YAMANO, Michael
EMMETIERE, Fabien
AMEGADZIE, Albert
LI, Yunxiao
JACKSON, Jeffrey
MEDINA, Jose
NAVARATNE, Primali
WURZ, Ryan
CHEN, Ning
ZHAO, Wei
RAHIMOFF, Rene
RUI, Huan
LANMAN, Brian
SIEGMUND, Aaron
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5131 | |
| EPO | Filing, Examination, Granting | 43618 | |
| Japan | Filing, Examination, Granting | 3416 | |
| South Korea | Filing, Examination, Granting | 4635 | |
| USA | Filing, Examination, Granting | 13710 |
Total:
70,510
Contact Us
Abstract[English]
The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S. G13D, Q61H. Q61L or G12C. The compunds have a general Formula I: (I) wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.[French]
La présente divulgation concerne des composés utiles pour l'inhibition de KRAS G12D, G12V, G12A, G12S, G13D, Q61H, Q61L ou G12C. Les composés ont une formule générale I : (I) les variables de la formule I étant définies dans la description. La présente divulgation concerne également des compositions pharmaceutiques comprenant lesdits composés, des utilisations desdits composés, et des compositions pour le traitement, par exemple, du cancer.